Maze Therapeutics Inc
MAZE45.030USD
+1.080+2.46%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
2.16B시가총액
손실P/E TTM
자세한 내용은 Maze Therapeutics Inc 회사
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Maze Therapeutics Inc 정보
종목 코드 MAZE
회사 이름Maze Therapeutics Inc
상장일Jan 31, 2025
CEOColoma (Jason V)
직원 수125
유형Ordinary Share
회계 연도 종료Jan 31
주소171 Oyster Point Boulevard, Suite 300
도시SOUTH SAN FRANCISCO
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호94080
전화16508505070
웹사이트https://www.mazetx.com/
종목 코드 MAZE
상장일Jan 31, 2025
CEOColoma (Jason V)
Maze Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
+3.00%
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Ms. Courtney J. Phillips
Ms. Courtney J. Phillips
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
+3.00%
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
8.94K
--
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
수익 분석
FY2025Q3
FY2025Q2
FY2024
기업이 아직 관련 데이터를 공개하지 않았습니다.
지역별USD
이름
수익
비율
United States
0.00
0.00%
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Mon, Nov 17
마지막 업데이트: Mon, Nov 17
주주
주주 유형
주주
주주
비율
Third Rock Ventures, LLC
11.27%
Frazier Life Sciences Management, L.P.
9.49%
ARCH Venture Partners
8.56%
Deep Track Capital LP
8.21%
Andreessen Horowitz
3.54%
기타
58.93%
주주
주주
비율
Third Rock Ventures, LLC
11.27%
Frazier Life Sciences Management, L.P.
9.49%
ARCH Venture Partners
8.56%
Deep Track Capital LP
8.21%
Andreessen Horowitz
3.54%
기타
58.93%
주주 유형
주주
비율
Venture Capital
33.58%
Hedge Fund
16.44%
Investment Advisor/Hedge Fund
13.23%
Private Equity
10.76%
Investment Advisor
10.02%
Individual Investor
1.88%
Family Office
1.01%
Research Firm
0.45%
Endowment Fund
0.19%
기타
12.44%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
154
41.80M
86.88%
+1.94M
2025Q3
111
39.53M
83.57%
-194.63K
2025Q2
100
42.58M
97.22%
+13.88M
2025Q1
93
44.69M
102.04%
+15.27M
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Third Rock Ventures, LLC
5.42M
11.27%
-1.60M
-22.78%
Nov 04, 2025
Frazier Life Sciences Management, L.P.
4.57M
9.49%
-1.00
-0.00%
Sep 30, 2025
ARCH Venture Partners
4.12M
8.56%
--
--
Sep 30, 2025
Deep Track Capital LP
3.95M
8.21%
--
--
Sep 30, 2025
Andreessen Horowitz
1.70M
3.54%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
1.33M
2.77%
+915.34K
+218.14%
Sep 30, 2025
Matrix Capital Management Company, LP
1.65M
3.44%
-832.50K
-33.49%
Sep 30, 2025
Alphabet, Inc.
2.41M
5.01%
--
--
Sep 30, 2025
VR Adviser, LLC
1.23M
2.56%
+1.23M
--
Sep 30, 2025
Logos Global Management LP
1.23M
2.55%
+615.39K
+100.57%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Virtus LifeSci Biotech Clinical Trials ETF
1.64%
Invesco Dorsey Wright SmallCap Momentum ETF
0.53%
ALPS Medical Breakthroughs ETF
0.39%
iShares Micro-Cap ETF
0.12%
iShares Russell 2000 Value ETF
0.04%
ProShares UltraPro Russell2000
0.03%
ProShares Hedge Replication ETF
0.03%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
Schwab U.S. Small-Cap ETF
0.02%
더 보기
Virtus LifeSci Biotech Clinical Trials ETF
비율1.64%
Invesco Dorsey Wright SmallCap Momentum ETF
비율0.53%
ALPS Medical Breakthroughs ETF
비율0.39%
iShares Micro-Cap ETF
비율0.12%
iShares Russell 2000 Value ETF
비율0.04%
ProShares UltraPro Russell2000
비율0.03%
ProShares Hedge Replication ETF
비율0.03%
iShares Russell 2000 ETF
비율0.02%
Proshares Ultra Russell 2000
비율0.02%
Schwab U.S. Small-Cap ETF
비율0.02%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
